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Resumo 
 
O presente relatório propõe relatar a minha experiência de 11 meses em 
farmacovigilância na Bluepharma - Indústria Farmacêutica, S.A. O estágio foi 
realizado no âmbito do mestrado em Biomedicina Farmacêutica e teve como 
objetivos a aquisição de competências técnicas e de experiência em 
farmacovigilância e a consolidação de conhecimentos.  
No primeiro capítulo é feita uma introdução ao estágio curricular, seguindo-se 
uma descrição do estado da arte da indústria farmacêutica, focando-se no 
mercado farmacêutico e no seu ambiente regulamentar na União Europeia, em 
especial na área da farmacovigilância. Neste capítulo é ainda apresentada a 
empresa de acolhimento e os objetivos do estágio. No capítulo seguinte são 
descritas as formações multidisciplinares, bem como as tarefas e atividades 
desempenhadas durante o período de estágio. No final é apresentada uma 
discussão e conclusão, incluindo uma análise das atividades desenvolvidas, 
principais dificuldades sentidas bem como das competências adquiridas 
durante esta experiência profissional. 
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abstract 
 
The present report intends to describe my 11-month experience in 
pharmacovigilance at Bluepharma - Indústria Farmacêutica, S.A. The 
internship was performed within the scope of the Master’s Degree in 
Pharmaceutical Biomedicine, aiming to acquire technical skills and experience 
in pharmacovigilance, as well as to consolidate previous knowledge.  
The first chapter introduces the internship and describes the state of the art in 
the pharmaceutical industry focusing on the pharmaceutical market and 
regulatory environment in the European Union, especially in the 
pharmacovigilance area. This chapter also includes a description of the host 
company and the internship objectives. The subsequent chapter presents a 
description of the multidisciplinary experience as well as the tasks and activities 
developed during the internship period. Finally, it is presented a discussion and 
conclusion, which include a critical analysis of the tasks developed, main 
difficulties and skills acquired during this professional experience. 
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1. Introduction 
The present work consists of a curricular internship report within the scope of the Master’s 
Degree in Pharmaceutical Biomedicine. The curricular internship occurred at Bluepharma - 
Indústria Farmacêutica, S.A. from June 2012 to May 2013. 
This report describes my working experience during 11 months at Bluepharma Indústria - 
Farmacêutica, S.A., as well as the learning outcomes and skills acquired during this period. 
For these purposes, this report will address the current state of the art in the pharmaceutical 
industry focusing on the pharmaceutical market and regulatory environment. A brief vision 
on the institution will be made and as well as the objectives proposed for my internship in 
the Regulatory Affairs and Pharmacovigilance department. 
Then, the multidisciplinary experience that was carried out to understand the objectives 
and activities performed in each company’s department as well as the understanding of 
how they interact, will be described. It will also be reported the specific experience gained 
by stating all the activities in which I participated during my internship in the Regulatory 
Affairs and Pharmacovigilance department. 
A brief discussion and conclusion will be presented at the end, discussing the different 
tasks assigned, the difficulties encountered during my internship as well as the skills 
developed and their relevance to my academic and professional development. 
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1.1. State of the Art  
This section intends to provide a brief overview of the current state of the art in 
pharmaceutical industry focusing on the pharmaceutical market, regulatory environment in 
European Union (EU) and pharmacovigilance. These topics are addressed since the main 
activities developed during my internship were related to the regulatory affairs and 
pharmacovigilance areas. 
 
Pharmaceutical market  
Pharmaceutical industry discovers, develops,  manufactures, and commercialises medicinal 
products which are designed to diagnose, prevent or cure diseases and consequently to 
enhance health and/or quality of life and prolong the average lifetime [1]. 
In 2012, Pharmaceutical companies invested an average of more than $1.3 billion 
developing a single innovative new medicinal product. The research-based pharmaceutical 
industry contributed to medicinal progress throughout the translation of fundamental 
research into innovative treatments. The increase in scientific knowledge and the 
development of new technologies have contributed to improve and maintain health and 
increase the life expectation [2-4]. 
According to European Federation of Pharmaceutical Industries and Associations’ report 
of 2012, “the world pharmaceutical market was worth an estimated €614,583 million at ex-
factory prices in 2011”. The world’s largest market remains the North American market 
followed by European and Japanese [2].  
The originator companies spend a large amount of money and time investigating and 
developing new products. In Europe, innovation is protected at two different parallel 
levels, by standard commercial laws, through patents and supplementary protection 
certificates, and by specific “health laws” that specifically govern generic medicinal 
products development (data protection period of 8 years) and marketing (market 
exclusivity period of 10 years), since the initial authorisation of the reference product is 
granted. Generic medicinal products applications can only be submitted to the CA after the 
data protection period and can only be placed on the market after the market exclusivity 
period [5]. 
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In 2009, the generic medicines market had an estimated value of €57 billion in the top 
global markets. In Europe, European Generic Medicines Association estimated that the 
generics medicines market size was of €31 billion in 2009 [6]. 
In contrast to the general perception, the generic medicine companies also contribute to 
innovation. A large amount of generic medicines companies invest a significant amount of 
their budgets on innovation. This innovation is related to the creation of  new strategies to 
overcome patents that may cover active pharmaceutical ingredient (API) substances or 
manufacture processes of a finished product, new technologies by means of the 
improvement of the existing formulations as well as new systems to increase patient 
compliance [6].  
To maintain the sustainability of healthcare systems, one important factor is the cost of 
medicines. Over the years, pharmaceutical expenditure has been growing in Europe and it 
is possible to predict that this expenditure will not undergo a reduction in the coming years 
due to the aging population increase and changes in the  European citizens life style [6, 7].  
The economic and financial crisis in the EU enhance the need to have effective and 
efficient healthcare systems and adequate management with the strain resources available 
[7]. Consequently, the generic medicines play an important role in healthcare systems, 
treating diseases at lower costs and consequently increasing the accessibility and 
affordability of essential medicinal products to patients [6].  
Despite the advantages presented by generic medicines some companies of originator 
products, health care professional and patients still do not fully trust this type of medicines, 
arguing that they may be less safe and effective and have less quality than the branded 
medicines [8].  
Any type of medicinal product can only be marketed in the EU once they have been 
approved by the European Medicines Agency (EMA) or National Competent Authorities 
(CA) [9]. Regulatory authorities aim to protect public health, so the generic medicinal 
products must fulfil stringent and science-based standards of efficacy, quality and safety as 
an originator medicine in order to grant a marketing authorisation (MA) and ensure that 
they are not a threat for public health [7, 8]. 
In order to grant a MA to a generic medicinal product, this must contain the same active 
ingredient as the originator reference product, be identical in pharmaceutical form, route of 
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administration and strength, be bioequivalent and manufactured according to Good 
Manufacturing Practice (GMP) regulations [8, 9].  
Consequently, the companies must submit quality, efficacy and safety data, including 
clinical data that proves the bioavailability and bioequivalence of the generic medicine vs. 
originator reference products to the regulatory authorities, which will be reviewed with the 
same accuracy than the innovator reference medicinal product already approved [9].  
 
Pharmaceutical Regulatory Environment  
Medicinal products are among the most stringently regulated products in the world. 
Extensive and complex regulations have been developed due to the need of safeguarding 
public health. Nevertheless, this has not been a simple process. Current regulations were 
developed overtime, and the huge advances in regulatory development were triggered by 
adverse incidents [10]. 
The pharmaceutical regulation is based on four main principles and concepts which are 
safety, efficacy, quality and risk-benefit [10].  
Between the decade of 60s and 70s, it was observed a rapid increase in the regulatory 
requirements concerning safety, quality and efficacy data of medicinal products submitted 
to the regulatory authorities. Simultaneously, the pharmaceutical industry started its 
internationalisation process, seeking new global markets [10]. The internationalisation of 
the pharmaceutical industry is not a simple process, since pharmaceutical industry finds 
different technical and administrative requirements from country to country. To market 
new worldwide products,  companies had to duplicate various test procedures, which were 
time-consuming and expensive [11].  
Consequently, an urgent need to harmonise regulation emerged due to several concerns 
like the over rising costs in health, the increasing costs of Research and Development 
(R&D) and the delay in the availability of new treatments to patients [1].  
The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) initiative joins medicinal products 
regulatory authorities and the pharmaceutical industry of Europe, Japan and the United 
States and contributes to the harmonisation in the interpretation and application of 
technical guidelines and requirements for pharmaceutical product development and 
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registration at an international level. The harmonisation process results from a process of 
scientific consensus with regulatory bodies and industry working together to the 
development of ICH Tripartite Guidelines [12].  
One of the most important contributes of the ICH was the creation of the Common 
Technical Document (CTD), through an Industry proposal in 1996. This document 
revolutionised the submission process for pharmaceutical companies as well as for 
regulatory authorities. The CTD, and, since 2006 the electronic CTD, allow time and 
resources saving since instead of multiple complex submissions it is possible to submit a 
single technical dossier in the three ICH regions [13]. 
Consequently a new regulatory language was created facilitating simultaneous submission, 
approval, and launch of new multi-market medicinal products and promoting faster access 
to life-saving treatments to patients beyond ICH regions [12].  
 
European Legislation 
Over the years, stringent legislation and requirements have been developed concerning the 
R&D of medicinal products, MA approval, promotional practices and monitoring of the 
safety of medicines during development and post-authorisation phases [14].  
The European legislation related to medicinal products for human use is composed by a set 
of legal instruments, organised hierarchically as presented in Figure 1 [5].  
 
Figure 1 - Overview of the hierarchy of Community texts 
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The European pharmaceutical legislation is compiled in a set of publications globally 
named Eudralex. Volume 1 to Volume 5 of Eudralex, compile the body of the EU 
legislation in the pharmaceutical sector; Volume 1 is related to medicinal products for 
human use and Volume 5 concerns medicinal products for veterinary use. The basic 
legislation is supported by a set of guidelines published in the other different volumes 
(Volume 2 to Volume 10), according to the pharmaceutical area of interest [15]. 
The main objective of the European Regulation is to safeguard public health. For that, 
three main areas of activity are taken into attention by the regulatory authorities: product 
development, product manufacture and market vigilance [10]. 
Product development – pre-authorisation phase 
To commercialise a new product, the company that is developing the product must 
generate sufficient data to demonstrate the efficacy, safety and quality of the product. This 
information is submitted to the regulatory authorities for review in the CTD format as 
referred above [14].  
The CTD structure comprises five modules containing non-clinical, clinical and quality 
information as presented in Figure 2. Module 1 contains the regional and administrative 
information and it is specific for each region (not being considered part of the CTD). The 
other four modules are common to the three regions and are in an harmonised format [16]. 
 
Figure 2 – Common Technical Document reproduced from reference 17 
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If the information is satisfactory, the regulatory authorities will grant a MA. The approved 
MA is valid for 5 years and should be renewed at the end of that period. After having an 
approved MA, the product shall be placed on the market within a period of three years 
(“sunset clause”) [17].  
 
Product manufacture  
The manufacture process is also an important area for the regulatory authorities [18]. The 
pharmaceutical industry activity is governed by a set of norms and procedures of legal 
framework that constitute the GMP. The GMP include the basic requirements for 
medicinal products (Part I), basic requirements for active substances used as starting 
materials (Part II), GMP related documents (Part III) and Annexes. GMPs cover the 
following areas: 
 Quality Management 
 Personnel 
 Premise and Equipment 
 Documentation 
 Production 
 Quality Control 
 Contract Manufacture and Analysis 
 Complaints and Product Recall 
 Self-Inspection 
All medicinal products manufacturers for human use have the obligation to possess a 
manufacture authorisation for the manufacturing of their products and a GMP Certificate. 
These documents are issued by EU National CA after verification and inspection of the 
activities and procedures implemented in the pharmaceutical  facilities/sites [9, 18]. 
Manufacturing sites  must follow the principles and guidelines of the GMP assuring that 
the production of medicinal products is performed and controlled according to quality 
standards [9, 18]. 
National CA perform regular inspections to the sites in order to verify the compliance with 
GMP principles and relevant regulatory requirements [14].  
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Pharmacovigilance 
When a MA is granted, it does not mean that the medicinal product does not have any 
safety issue. It only means that, based on the current scientific knowledge, the benefits 
outweigh identified risks. 
This concept is very well established by a statement of the Committee on Safety of Drugs, 
which clearly states that “No drug which is pharmacologically effective is entirely without 
hazard. The hazard may be insignificant or may be acceptable in relation to the drug's 
therapeutic action. Furthermore, not all hazards can be known before a drug is 
marketed”[19]. 
It is recognised that, the information concerning the safety and efficacy information of the 
medicinal product is limited since the information is based on a reduced number of patients 
that were studied only under the controlled conditions of randomised clinical trials. No 
long-term treatment data is available and the inclusion criteria is narrow, in clinical trials 
higher risk subgroups are not included nor patients with concomitant illnesses that require 
use of other medicinal products. These factors underlie the need for continuing to analyse 
and assess relevant safety and effectiveness information throughout the medicinal 
product’s lifecycle [14, 20]. 
According to World Health Organisation (WHO), pharmacovigilance is “the science and 
activities relating to the detection, assessment, understanding and prevention of adverse 
effects or any other medicine-related problem” [21]. The regulatory authorities put in place 
systems for a systematic collection and assessment of information about adverse drug 
reactions (ADRs), over the product’s lifetime. These systems allow to identify risks that 
did not surface during the pre-marketing phase and that only are possible to identify in real 
life conditions [20].  
Medicines bring, to patients, many benefits to health such as the improvement of quality of 
life, prevention of millions of deaths (with vaccination and antibiotics and treatment of  
cancer and heart diseases’) [22].  
However, in 2008 the European Commission (EC) published their proposals for 
strengthening pharmacovigilance framework, concluding that [22]:  
 Approximately 5% of all hospital admissions are due to ADRs; 
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 ADRs are the fifth most common cause of hospital death; 
 ADRs cause 197,000 deaths each year; 
 In EU, ADRs represent, to society, a total cost of €79 billion.   
Indeed, ADRs are associated to high morbidity and mortality being a serious public health 
issue [22]. 
To improve the public health protection new European pharmacovigilance legislation was 
prepared and subsequently adopted in December 2010 and most legal measures began to 
be applied on 2 July 2012. The new legislation comprises the Directive 2010/84/EU of 15 
December 2010 amending Directive 2001/83/EC and the Regulation No 1235/2010 of 15 
December 2010 amending Regulation No 726/2004. The Regulation became immediately 
enforceable in all Member States and the Directive was transposed to the Portuguese 
National Law by means of the publication of the Decree-Law 20/2013 of 14 February [23, 
24]. This change in the European legislation, is considered the biggest change in regulation 
of human medicinal products since 1995 having an impact on the entire product life cycle 
[23, 24]. 
To support the new legislation on pharmacovigilance and to facilitate the performance of 
pharmacovigilance in EU, a new set of guidelines - good pharmacovigilance practices 
(GVP) - were developed and, once adopted, will replace the current Volume 9A of the 
Rules Governing Medicinal Products. In total, there are 16 GVP modules covering all 
major pharmacovigilance processes. At the moment, most modules are already in force and 
it is expected that the full set of modules will be available during the present year [23, 24]. 
The new legislation on pharmacovigilance is focused on [9, 22, 23, 25]:  
1. The collection of information concerning the medicinal products based on risk 
management plans (RMP) (which became required for the submission of all new 
medicinal products), periodic safety update reports (PSUR) and post-authorisation 
safety and efficacy studies for which stronger requirements are demanded; ADR 
reporting by patients (which involves the implementation of direct consumer 
reporting of suspected ADR systems); 
2. The use of the EudraVigilance (EV) database for signal detection through the 
analysis and understanding of available data and for submission of PSUR, RMP, 
ADR and information concerning all the medicinal products authorised in the EU; 
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3. Additional monitoring of medicines through the publication of a list of medicinal 
products subject to additional monitoring, the addition of an inverted black triangle 
to the medicinal product’s information of the products included in that list with a 
standardised sentence and the inclusion of a standardised text that encourages ADR 
reporting for all medicines; 
4. Creation of a new EMA’s Committee, Pharmacovigilance and Risk Assessment 
Committee (PRAC), with the objective of promoting and safeguarding public 
health, reinforcing referral procedures and implementing a robust EU decision-
making on safety issues;  
5. Increase of the communication and transparency with different stakeholders by 
mean of the publication of information concerning medicinal products approved in 
EU, public hearings, as well as, coordination of safety messages between the MS. 
 
National Pharmacovigilance System 
In Portugal, the pharmacovigilance system was created in 1992, being the National 
Authority of Medicines and Health Products, I.P (INFARMED, I.P.) responsible for the 
coordination of the National Pharmacovigilance System [26]. The National 
Pharmacovigilance System is formed by the Directorate of Medicines Risk Management, 
the Regional Pharmacovigilance Units (North Pharmacovigilance Unit, Center 
Pharmacovigilance Unit, Lisboa and Vale do Tejo Pharmacovigilance Unit and South 
Pharmacovigilance Unit), healthcare services, including health care professionals and sales 
representatives, Marketing Authorisation Holders (MAHs) and patients [26]. 
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1.2. Vision on the Institution 
Bluepharma - Indústria Farmacêutica, S.A. is a pharmaceutical company based at Coimbra. 
It was founded in February 2001, with Portuguese capital only, by a group of Portuguese 
professionals who acquired Bayer’s industrial unit.  
Bluepharma - Indústria Farmacêutica, S.A. initiated its activity as a contract manufacturing 
organisation, manufacturing product (bulk or finished product) to other pharmaceutical 
companies.   
As time went by, Bluepharma broaden their horizons and goals and the company’s strategy 
changed and in addition to the production of pharmaceutical medicinal products, they  also 
started investing in the investigation and development of new technologies, starting this 
activity as a contract research organisation. In 2003, Bluepharma created the department of 
Research & Development and its first affiliate Bluepharma Genéricos – Comércio de 
Medicamentos, S.A.  
Currently, Bluepharma maintains the manufacturing of medicinal products for other 
companies and for itself but also develops products/technologies and provides services to 
different clients. The company offers out-licencing by licencing technologies to other 
companies according to predetermined rules established in licence agreements and product 
supply agreements. 
The main business activities of Bluepharma are the following: 
 Production of medicinal products for other companies; 
 Production and commercialisation of own brand of generic medicinal products - 
Bluepharma Genéricos – Comércio de Medicamentos, S.A. 
 Research, development and registration of pharmaceutical medicinal products; 
 Licensing of new technologies. 
Bluepharma is authorised to manufacture different non-sterile products in the following 
solid dosage forms: capsules, hard shell, tablets, powder and granules. It is a GMP 
certificated company by INFARMED, I.P., the company obtained an environmental 
certificate Eco-Management and Audit Scheme and in 2009, became the first Portuguese 
pharmaceutical company obtaining the Food and Drug Administration certification. 
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Also, Bluepharma faces the future investing in emerging fields such as oncology, 
nanotechnology and biotechnology by establishing partnerships with multinational 
pharmaceutical companies, local and international research centers. 
The organisational chart of Bluepharma is presented in Figure 3 [27]. My curricular 
internship occurred in the Regulatory Affairs and Pharmacovigilance department. 
The Regulatory Affairs and Pharmacovigilance department is constituted by six 
collaborators. The majority of the team elements has a degree in Pharmaceutical Sciences 
and several years of experience in pharmaceutical industry. Consequently, this was for me 
a very enriching experience. 
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1.3. Internship Objectives 
This internship had the objectives of developing skills/competences acquired during the 
Degree in Biomedical Science and in the Master Degree in Pharmaceutical Biomedicine 
and gaining new personal and work capacities and competences. The following objectives 
were established: 
  
Hard skills 
 To identify the organisational structure of Bluepharma and its main areas of activity 
 To identify the Regulatory Affairs and Pharmacovigilance structure and its 
interaction with other departments namely Research & Development, Quality 
Control, Quality Management and Product Quality & Compliance 
 To understand the pharmacovigilance legislation as well as the GVP 
 To participate in the preparation and implementation of Pharmacovigilance System 
Master File (PSMF) 
 To participate in the reformulation of Bluepharma’s pharmacovigilance system, 
according to new pharmacovigilance obligations 
 To prepare PSURs to the CA 
 To participate in the preparation of RMPs 
 To perform bibliographic search 
 To understand and participate in individual case safety report (ICSR) collection, 
processing, assessment and reporting to CA 
 To participate in the submission throughout EV Database of Bluepharma’s 
medicinal products-related information 
 To get acquainted with the Scientific Service structure 
 To participate in Scientific Service activities’ 
 To get acquainted to the CTD structure as well as to the specificities of each 
module of the document 
 To participate in exportation-related activities:  
 To identify the regulatory requirements for the registration of medicinal 
products in 3
rd
 world countries as Mozambique and Cape Verde 
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 To elaborate/prepare and submit the specific documentation (product 
dossier and support material) for the registration of medicinal products in  
Cape Verde and Mozambique 
 
Soft skills 
 To contact with the working environment in a pharmaceutical company  
 To develop skills of different types, such as organisational skills, time management, 
problem solving, responsibility sense, critical thinking, accuracy and attention to 
details 
 To improve communication skill (verbal and written) 
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2. On-the-Job Training  
This chapter intends to describe all the activities, tasks developed, and learning outcomes 
acquired during my curricular internship at Bluepharma. 
For that, this chapter is organised in two sections: 
 Multidisciplinary experience in which is described the training sessions 
attended. Some of them were mandatory for all collaborators and others were 
essential to understand the life cycle of a generic medicinal product and to 
perform the tasks and activities assigned during my internship. 
 Specific experience in which is described my experience in the Regulatory 
Affairs and Pharmacovigilance department and the tasks and activities 
developed. 
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2.1. Multidisciplinary Experience  
During my internship at Bluepharma, I attended different types of training sessions: ones 
that were mandatory for all collaborators, internal training sessions to acquire knowledge 
concerning different departments that closely interact with the Regulatory Affairs and 
Pharmacovigilance department and specific training sessions that allowed me to develop 
the different tasks and activities during my internship (Figure 4). 
 
Figure 4 – Summary of training sessions attended during the internship period 
 
Bluepharma is a certified company and consequently the integration of new collaborators 
comply with certain requirements namely training/information sessions concerning the 
main rules and principles of different areas of the company.  
Consequently, when I started my curricular internship, I needed to acquired knowledge in 
general areas that were transversal to all company departments. This was done through 
self-reading of the company’s quality manual and internal Standard Operating Procedures 
(SOPs) and training sessions. 
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I attended general internal training sessions concerning the following issues (Figure 4): 
 Bluepharma Quality  Management System  
 Innovation and R&D certification 
 Environment and safety management system 
 GMPs 
 Information technology services 
 CTD contents and regulatory requirements 
Aspects addressed in the several training sessions included Bluepharma’s certifications, 
GMPs, CTD modules, type of authorisation procedures and regulatory requirements. 
Training on critical/relevant information technology internal SOPs and policies were also 
part of the general internal training sessions. 
Those training sessions were very useful to refresh some concepts learned in my academic 
journey, such as quality systems, on CTD and on MA procedures as well as to acquire new 
concepts. During some of the sessions it was highlighted the importance of GMP and 
national and international regulations and their compliance in all the departments of the 
company.  
Over the time, I also attended some additional brief formative sessions, named “paper 
clubs”, which addressed different knowledge areas.  
In order to understand how the company departments interact with each other, and to 
understand the company’s dynamic and how the several departments work by themselves, 
I visited and had training sessions, according to a predefined schedule (Figure 4), in several 
departments such as R&D, Business and Development, Production and Packaging, Quality 
Control, Product Quality & Compliance and Quality Management departments. 
 
2.1.1. Research & Development 
In May, I followed the activities developed in the R&D department for a day. The 
objective of this observational training was to learn the basic principles of the 
pharmaceutical development process and how projects result in new products. 
The R&D laboratory of Bluepharma is responsible for developing investigational projects, 
being responsible for the different stages of the development of products, namely 
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development of pharmaceutical formulations, development and validation of analytical 
methods, stability studies, manufacturing process development and up-scaling.  
The development of generic medicinal products have different stages as it is described 
below: 
1. Selection of the product; 
2. Compilation of all possible information concerning the product, such as its description, 
pharmaceutical form, packaging material, sales of the innovator medicinal product,  
expected sales for the generic medicinal product, special manufacturing requirements, 
manufacturing site, intended  batch size, and other relevant information; 
3. Formulation development 
3.1. Characterisation of the innovator medicinal product and its API in order to select 
an appropriate formulation and the adequate manufacturing process; 
3.2. Characterisation of the drug product, namely in what concerns to the appearance, 
average weight, water content, hardness, disintegration, dissolution, content and 
related substances; 
3.3. Characterisation of the packaging material; 
3.4. Physicochemical characterisation of the API; 
3.5. Formulation development, focused on having  similar dissolution profiles, as well 
as, impurity profiles, between the innovator reference product and generic 
medicinal product; 
3.6. Characterisation of the mixture (water content and  homogeneity of the mixture) 
and the finished product (appearance, average weight, uniformity of mass, 
hardness, disintegration and dissolution); 
4. Development and validation of analytical methods 
In this phase, it is intended to develop and validate analytical methodologies that will be 
used to evaluate the API and finished product, as well as, any relevant intermediate product 
(i.e.: mixture or granules). The validation of a method allows to demonstrate that it is 
suitable for its intended purpose. 
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5. Laboratory batches 
Laboratorial batches, which have a very small size, are produced, at early development 
laboratory stage, in order to assess and define critical product characteristics and 
consequently to select the appropriate manufacturing process.  
6. Pilot-batches production   
Pilot-batches are manufactured (in representative equipment) and controlled according to 
the data obtained in the steps above. For oral solid dosage forms, the pilot-batch size 
should corresponds to at least 100 000 units or at least 10% of the future industrial scale 
batch, whichever is greater. The pilot-batches are produced, packaged, and submitted to the 
ICH stability programme.   
These batches will be used to feasibility studies, validation of the manufacturing process, 
up-scaling studies, stability studies and bioavailability-bioequivalence studies. The 
information obtained will be used in industrial batches manufacturing. 
7. Stability studies  
Stability studies are conducted to assess how the physicochemical stability of the product 
varies with time under the influence of different storage conditions (temperature, humidity 
and light) and to establish/propose a shelf-life for the medicinal product and recommend 
storage conditions, if needed [28]. Bluepharma follows the ICH guidelines. 
The world is divided in four different climatic zones (I, II, III, IV). According to the 
climatic zone, the stability studies have different storage conditions and duration [29]. 
This day in R&D department, revealed a great opportunity to observe some processes used 
during the development of a product such as wet granulation, drying process and 
compression in laboratory scale. Since I have a degree in Biomedical Science, I have a 
limited knowledge in this area. I considered this day very helpful because I understood 
how a product “is born”. I got the opportunity to observe and participate in several 
processes that allowed me to comprehend many concepts that I had dealt with in many of 
my tasks in the Regulatory Affairs and Pharmacovigilance department, where the work 
relied on the product after being commercialised.  
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2.1.2. Business and Development  
In May, I had a training session in the Business and Development department. Several 
themes were addressed namely: activities performed in this department, markets in which 
Bluepharma is present, intellectual property, pricing and reimbursement and the 
concerning legislation. 
 
2.1.3. Production and Packaging 
In May, I had the chance to accompany the activities conducted on the production and 
packaging department for two days. All the manufacturing processes have a manufacturing 
procedure that describe all the stages to be followed in the manufacturing process which 
are listed in the manufacturing protocol/record that is filled-in during the stages of the 
process.  
To initiate the manufacturing process, the informatics system (SAP) generate a 
manufacturing order concerning to a specific batch. During the manufacturing process, the 
manufacturing protocol/record is filled-in and attached with all the relevant information, 
such as  weigh registries, in-process controls (IPCs), and relevant manufacturing times 
(process duration and process ending times); at the end, all the information is compiled and 
verified, and it is performed yield calculation.  
I had the opportunity to accompany different processes that are performed in this 
department: 
1. Weighing 
Weighing is the start line. All raw materials (API) and excipients are weighed, after 
being entered in the SAP’s system. This process is performed during several stages 
of the production of a medicinal product; mixtures before compression, or 
encapsulation, semi-finished product before packaging or bulk product for sale. 
Weighing is performed in suitable rooms and the operators must use personal 
protective equipment is accordance with the safety sheets of the product that will be 
handled.  
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2. Granulation 
 Wet granulation 
Granulation is performed in order to improve the characteristics of the mixture of 
the API, i.e., increase of the particle size, improvement of the compression process 
and flow properties, improvement of the content uniformity and/or increase of the 
solubility of the API.  
This process has different stages such as the preparation of the granulation 
solution/suspension, the granulation itself (mixture of the solids to be granulated 
with granulation solution/suspension), final sieving of the wet granulated mass and 
the drying process of the obtained granules. 
 Dry granulation 
When the raw material characteristics do not allow a wet granulation process, other 
type of granulation, named dry granulation, may be used.  
This type of granulation is a manufacturing process used to modify the 
pharmacotechnical properties of a product in order to facilitate the process of 
compression or encapsulation. In this process, there is the aggregation of particles 
by compaction (e.g.: roller compaction) which are then milled or sieved to the 
desired size. 
3. Compression 
The tablets are obtained by compression, which may be a direct powder mixture 
compression or granulate compression. Bluepharma has different compression 
machines, which are fed vertically in order to prevent contaminations and product 
loss.  
The compressor has a combined unit constituted by a deduster, which makes the 
dedusting of the surface of the tablets and a metal detector that detects metal 
particles that tablets may contain. 
4. Coating  
In some cases, the tablets are subjected to a coating process in order to cover 
unpleasant tastes and odours, facilitating swallowing, improving product stability 
and/or modifying the release profile or for aesthetical reasons. 
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This process takes place in an automated equipment and consists on the 
pulverisation of the tablets with a coating agent suspension and subsequent drying. 
5. In-process control  
IPCs are conducted in regular intervals of time, during all the stages of the 
manufacturing process, in order to ensure the quality control and the process 
control.  
Several parameters may be monitored taking into account the product that is being 
manufactured and the related manufacturing process. Examples of IPCs include 
appearance, average weight, disintegration, length, hardness, friability and in 
closure system (capsules case). 
6. Packaging  
Bluepharma is responsible for the packaging of some products derived from the 
production as well as products acquired in bulk; the packaging is performed not 
only for Bluepharma Genéricos but also for other clients. 
There is a Packaging Protocol for each product, and as in production, the packaging 
process may only begin once the Packaging Order is processed by the informatics 
system (SAP). The materials are informatically requested with the Packaging Order 
generation and are sent to the packaging sector, as soon as approved by the Quality 
Control. 
All the instructions are detailed in the packaging procedure and during the process, 
the line collaborators register in the packaging protocol relevant information. All 
the information concerning a batch is compiled and attached, being sent to the 
Product Quality & Compliance and Quality Control. 
Accompanying these processes was an enriching experience since I had the opportunity to 
acquire theoretical competences concerning medicinal products’ manufacturing and 
packaging that will be useful to develop my future work.  
 
2.1.4. Quality Control 
In May, I followed some of the activities performed in the Quality Control department for 
one day. This department is responsible for all the quality control activities that are set out 
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in the analytical protocols and that are required to ensure the medicinal products 
compliance with the GMP and applicable legislation. 
All raw materials, packaging materials, intermediate products, bulk products and finished 
product are subjected to a sampling process in order to verify the product characteristics 
and confirm its compliance with applicable the specifications. Microbiologic and 
physicochemical tests are performed and the samples are stored. In accordance with the 
results, appropriate measures are taken. 
 
2.1.5. Product Quality & Compliance 
In April, I had a training session in the Product Quality & Compliance department for two 
days.  
In that department, I had the opportunity to understand how the process of product release 
is performed. A brief overview of the process accompanied is provided below. 
Product release 
All the products produced at or for Bluepharma (bulk or finished product), to be release for 
selling or for supplying, must have a release authorisation that is a responsibility of the 
Qualified Person. 
A certificate of release concerning the product for sale or a Certificate of Product 
Compliance (for bulk products) is emitted to authorise the effective release of the product 
to the client/market.   
The Product Quality & Compliance department receives and verifies all the documentation 
concerning the production and/or packaging and quality control of the product’s batch; the 
internal approval of all its components is performed by the Quality Control. The emission 
of the compliance certificate and the release of all products is a responsibility of the 
Qualified Person. 
The last step of this process is to send the documentation concerning the product’s 
approval/release to the client according to the technical agreement signed between 
Bluepharma and the client. 
I also had the chance to attend a meeting to discuss the preparation of a manufacturing 
procedure and the respective manufacturing protocol.  
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2.1.6. Quality Management  
Bluepharma has implemented a Quality, Environmental, Health and Safety Management 
System. A management system is what the organisation has in place to manage their 
processes or activities in order to assure, monitor and promote that the products/services 
efficiently achieve their objectives [30]. 
Bluepharma’s quality system is implemented throughout the product lifecycle enhancing 
an innovator and continual improvement and strengthening the link between 
pharmaceutical development and manufacturing activities. 
In 2003, Bluepharma obtained a combined certification in Quality, Environment, Safety 
and Occupational Heath supported by International Organization for Standardization (ISO) 
Norms 9001, ISO 14001 and Occupational Health and Safety Advisory Services 18001 and 
Regulation No 1221/2009; recently obtained the certification in Portuguese Norms of 
Research, Development and Innovation.  
I also had the possibility to observe other activities developed by the department such as 
change control processes, supplier management process, SAP management and customer 
satisfaction surveys analysis.  
 
After these training sessions, I concluded that it was a very useful and fruitful experience. I 
had the possibility to be in touch with different areas, and acquire different 
skills/competences concerning the medicinal product life cycle, since the moment that a 
new project is planned to its preparation for the market phase. The purposes of these 
training sessions were to know the activities performed in each department and be 
familiarised with the processes and support documentation used.  
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2.2. Specific Experience 
This section describes the main activities performed in the Regulatory Affairs and 
Pharmacovigilance department. The main activities developed during my internship were 
related to the pharmacovigilance area and consequently, this section is focused on this 
field. However, I also accompanied scientific service and exportation activities, and that 
are also included. 
 
2.2.1. Pharmacovigilance 
 
2.2.1.1. Pharmacovigilance System Master File 
Overall requirements 
The new pharmacovigilance legislation introduced the concept of the Pharmacovigilance 
System Master File (PSMF) [23]. PSMF details the pharmacovigilance system used by a 
MAH to cover one or more authorised medicinal products. It contains summarised 
information and key documentation that cover all the pharmacovigilance activities aspects 
[31]. 
For centralised procedures, after 2 July 2012, as well as for National submissions, after 21 
July 2012, all new MA, must present a PSMF. All medicinal products approved before 
these dates have a deadline to have available this document (transitional period until July 
2015). 
PSMF does not have an available template. However, the Commission Implementing 
Regulation and GVP Module II describe its content and structure.  
 
Working experience 
During my internship period, I had the chance to collaborate in the preparation and 
implementation process of the company’s PSMF. The pharmacovigilance service 
collaborators jointly prepared the PSMF. For that, we had to analyse the EU legal 
requirements and relevant GVPs in order to create the company’s PSMF [23, 32]. Finally, 
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we compiled the information required and wrote the different sections of the PSMF, which 
are described below: [10, 23]: 
 Qualified person responsible for pharmacovigilance (EU-QPPV) information 
section  
 Responsibilities of the EU-QPPV (that detains the responsibility over the 
pharmacovigilance system) 
 Summary of the curriculum vitae of the EU-QPPV (including a proof of 
registration in the EV database) 
 Contact details of the EU-QPPV 
 Nomination of the EU-QPPV deputy 
 The organisational structure of the MAH 
 The computerised systems and databases used 
 Pharmacovigilance processes  
 The quality system for the performance of pharmacovigilance activities 
Besides the core of the PSMF, there is a specific section for annexes, which was also 
prepared. The information presented in this section is very detailed and in continuous 
updating since we are working in a dynamic system. 
Once the PSMF was prepared, it was registered in the eXtended EudraVigilance Medicinal 
Product Dictionary (XEVMPD). An acknowledgement was sent by the system (via EV) to 
the MAH, which confirmed the success of the registration. This registration, allowed the 
PSMF to have a code number associated to where it was located. This is the information 
required by the authorities. However, the authorities can request the PSMF itself and the 
MAH has a period of seven days to make it accessible to them. 
When I started my internship, the pharmacovigilance service was planning the preparation 
and implementation of the PSMF as well as the summary of the pharmacovigilance system 
required for MA applications. This was a very important and challenging activity since it 
allowed me be involved in the implementation of a new system and to acquire knowledge 
in the new legislation on pharmacovigilance. 
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2.2.1.2. Pharmacovigilance Quality System  
Overall requirements  
In accordance with the new pharmacovigilance legislation, the MAH has the obligation to 
have in place adequate and effective quality systems for the performance of their 
pharmacovigilance activities. The Commission Implementing Regulation No 520/2012 
defines the minimum requirements of the quality systems which should cover company 
organisational structure, responsibilities, procedures, processes and appropriate human 
resources, management of resources, compliance management and record management 
[32]. 
Since the company’s procedures in place before the new legislation on pharmacovigilance 
were not enough to comply with the new requirements, the company’s processes and SOPs 
were reviewed and new ones were created.  
 
Working experience 
I had the opportunity to participate in the planning, redesign and in the restructuration 
process of the pharmacovigilance system implemented by the company. 
First, the pharmacovigilance service collaborators’ performed a meeting in order to discuss 
the new requirements of the pharmacovigilance legislation and to define new processes and 
procedures to be implemented and the way they would be executed, in which I contributed 
giving some ideas. 
After designing and planning the new pharmacovigilance system, the existing SOPs were 
reviewed and new ones were created as well as their respective related-forms. I was able to 
contribute and participate in this task.  
The main areas covered by the prepared processes and procedures were the following [32]: 
 Risk minimisation system(s) and monitoring of the outcome of risk minimisation 
measures;  
 PSUR scheduling, preparation and submission; 
 ADR collection, collation, validation, follow-up assessment and reporting to the 
CA; 
Health Sciences Department 2013 Masters in Pharmaceutical Biomedicine 
 
30    
 Signal detection and analysis; 
 Communication of safety concerns to the CA, healthcare professionals and 
consumers;  
 Safety issues. 
This task revealed itself very challenging since several areas were involved and each one 
had different specificities. These activities helped me to understand how different SOPs are 
prepared and implemented in a pharmaceutical company with a certified quality system. In 
addition, it was helpful since it allowed me to be in touch with all the pharmacovigilance 
activities and understand how the pharmacovigilance activities would be performed after 
the system is implemented. I also gained experience in SOPs writing, which is a highly 
valued skill in this area. 
The application of the new legislation is not a static process and requires constant 
adjustments. Hence, the companies had to be attentive to sudden modifications, as it has 
been happening until now, for example, in the case of the publication of lists for the 
submission of PSURs or RMP and PSUR templates’, which can easily lead to non-
compliance, if not taken into account. 
Regarding this subject, I had an important role and responsibility on the monitoring, on a 
weekly-based, the most relevant regulatory bodies’ web sites and publications, such as 
EMA, INFARMED, I.P. and Heads of Medicines Agencies. The objective was to obtain 
the most updated information concerning all the pharmacovigilance issues and 
subsequently analyse and communicate the impact, if applicable, of such modifications on 
the implemented pharmacovigilance system.  
 
2.2.1.3. Individual Case Safety Reports 
The new pharmacovigilance legislation introduced a new definition of ADR. According to 
Directive 2010/84/EU, an ADR is defined as “a response to a medicinal product which is 
noxious and unintended.” “Response to a medicinal product” in this context means that a 
causal relationship between a medicinal product and an adverse event is at least a 
reasonable possibility [23]. This includes adverse reactions which arise from the use of a 
medicinal product within and outside of the terms of the MA, including overdose, off-label 
use, misuse, abuse and medication errors and also occupational exposure [23] 
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In accordance with the Directive 2001/83/EC as amended, ADR may be classified 
concerning the seriousness. An ADR is serious when results in death, life-threatening, 
requires patient hospitalisation or prolongation of existing hospitalisation, results in 
persistent or significant disability or incapacity, or in a congenital anomaly/birth defect 
[23].  
 
Processing ICSRs 
During my internship, I collaborated in the processing of ICSRs. This process encompasses 
four main stages: collection, validation, assessment, and report. 
 
1. Collection 
ADR can arise from unsolicited or solicited reports. Unsolicited reports are divided in 
spontaneous reports, literature reports and reports from other sources. Solicited reports 
arise from organised data collection systems as clinical trials, non-interventional studies, 
registries, patient or disease management programmes, surveys of patients or healthcare 
providers, and others [31].   
A spontaneous report is an unsolicited communication that describes one or more 
suspected ADR(s) in a patient who takes one or more medicinal product. This type of 
report is performed by a health care professionals or a consumer to the CA, MA or other 
organisation as the Regional Pharmacovigilance Centre [33]. 
 
Suspect adverse reactions from health professional and consumers 
According to my experience at Bluepharma, health care professionals and consumers can 
report a suspect ADR by different channels of communication such as the company’s 
website, telephone, email, fax, the company sales representatives and others. 
The information is processed taking always into account that the clock starts when 
someone in the company becomes aware of the suspect ADR and that depending on the 
seriousness of suspect ADR the reporting deadlines are different. Therefore, the 
information received is analysed and always recorded in internal databases.  
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During my internship, I had to process one case. Bluepharma was contacted by a health 
care professional and I had the chance to take the call and ask all the questions in order to 
obtain all the necessary information concerning the suspected ADR to process the case. 
After that, I also collaborated in the registration of the received information by filling-in 
the respective internal forms and by inserting the data in the databases.  
One of the responsibilities that was assigned to me was to maintain the ICSR databases 
(according to the information given to me). 
Suspect adverse reactions from literature search  
Scientific and medical literature provides important information concerning the safety and 
efficacy of medicinal products, allowing companies to monitor the benefit-risk profile of 
their medicinal products [33].  
According to their obligations, the pharmaceutical companies conduct a systematic 
literature review through widely used reference databases at least once a week for all active 
substances of their medicinal products with MA, irrespectively of commercial status. The 
literature search starts after the MA is granted and is performed during the product life 
cycle [33].  
During all my internship period, I assured the fulfilment of this pharmacovigilance activity. 
Thereby, I had to perform a systematic literature review, on a weekly basis, in order to 
comply with the regulatory requirements.  
Widely reference databases were used to perform the search, which was performed 
according to previously defined search criteria for all active substances of the company’s 
medicinal products. First, I received the articles, read their abstracts, and verified the 
information.  
Whenever a publication presented a case in which it was identified that the suspected 
medicinal product was an active substance of a Bluepharma medicinal product, an ICSR 
was created.  
To be a valid case, the publication had to fulfil the minimum criteria for reporting (see next 
section). The weekly search was always documented for compliance purposes. After 
analysing the publication, my function in this regard was to insert all the relevant 
information in an appropriate database and archiving the relevant documentation. 
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2. Validation 
The information received from the different sources needs to be verified in order to 
understand if it qualifies as a valid case.  
Therefore, according to GVP – Module VI, I verified if the case was considered valid or 
not. To be considered a valid case, it had to fulfil the minimum criteria for reporting [33]: 
 One or more identifiable reporter; 
 One single identifiable patient characterised by initials, patient identification 
number, date of birth, age, age group or gender; 
 One or more suspected substances/medicinal product; 
 One or more suspected adverse reaction. 
The information received can easy be incomplete and consequently, the reports need to be 
followed-up to obtain the detailed information required to analyse the case. There are two 
main types of follow-up: a follow-up to gather missing information or clarify misleading 
data; and a follow-up to complete or supplement a reported case, which is particularly 
important in cases as serious ADR or pregnancy exposure reports [33].  
In those situations, a request is usually sent to the primary reporter by means of a telephone 
call or if it is not possible, on an e-mail. 
Whenever a case report does not include the minimum criteria for reporting, even after the 
follow-up contact, the case is closed and only reported if additional information becomes 
available. Otherwise, if the case is valid, the next step is its evaluation. 
 
3. Assessment  
In accordance with the directive 2010/84/EU of 15 December 2012, the concept of ADR 
includes the existence of at least a reasonable possibility of a causal relationship between a 
medicinal product and the adverse event [23].  
In order to evaluate the relationship between the medicinal product and the observed ADR, 
various causality assessment methods are available. This evaluation may be performed by 
establishing algorithms, Bayesians systems or by making an evaluation after gathering all 
the information obtained from the reporter, the safety documents, the physician’s report 
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and all known safety information about the product in question. [34]. The following 
criteria are taken into account and analysed [26]: 
 Time relationship to medicinal product intake 
 Response to withdrawal plausible 
 Rechallenge data 
 ADR profile 
 Clinical and laboratorial findings  
 Seriousness and severity 
 Possible mechanism of action  
 Causality relationship 
 Predisposed factors 
 Reversibility and sequels  
 Pharmacological or phenomenological plausibility 
 Complementary investigational data 
 Concomitant diseases 
 Concomitant medicinal products 
The reference document used to evaluate the relevance of the information related to the 
ADRs received and the determination of the benefit-risk balance of a medicinal product is 
the suspect medicinal product’s summary of product characteristics (SmPC) available on 
the country where the suspect ADR occurred.  
One of my duties on this regard was to analyse the suspect medicinal product’s SmPC, in 
order to understand the expectedness of the ADR. An ADR may be classified as expected 
or unexpected: i.e., an expected ADR is described in the SmPC in terms of nature, severity 
and outcome. In the case of an unexpected ADR, none of this items are stated in the SmPC 
[23].  
Other of my roles was to verify if the description of the reported suspected adverse 
reaction was in accordance with the medical dictionary for regulatory activities (MedDRA) 
terminology, which was created for standardising the terminology used in regulatory 
information for medicinal products of human use.  
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During my internship, I accompanied the assessment of ICSRs by the pharmacovigilance 
service’s collaborators and medical advisor. At the end, it was decided whether a suspect 
adverse reaction is reported to the CA.  
 
4. Report of ICSR  
In accordance with the new pharmacovigilance legislation, the MAH and the Member 
State should communicate ADR electronically only through the EV database. The 
objective is to simplify the reporting of ADR and make available through a 
pharmacovigilance database the safety information concerning medicinal products on the 
EU [23, 33].  
The new legislation also introduced changes in the timeframe for the reporting of ADR, 
which currently are the following: 
 All serious ADR that occurred within the EU should be reported within 15 days; 
 All non-serious ADR occurred within the EU should be reported within 90 days 
(during the transitional period, only if required by MS); 
 All serious ADR occurred outside the EU should be reported within 15 days. 
EV database will allow the submission of ICSRs, but it is not yet completely functional. 
Consequently, in accordance with Directive 2010/84/EU, until the EMA can ensure the 
functionality of the EV database, there are being applied interim arrangements [23].  
EMA published a document entitled “Reporting requirements of Individual Case Safety 
Reports (ICSRs) applicable to MAH during the interim period” which defines the 
requirements of ICSR reporting depending on the MA procedure, origin, ADR type and 
destination MS. 
In accordance with the Decree-Law No 176/2006 of 30 August, amended by the Decree-
Law No 20/2013 of 14 February, and until the EV database is concluded, INFARMED, 
I.P. does not require the notification of non-serious ADR (only when expressly solicited). 
However, the MAH is responsible for analysing and recording all these cases and present 
them whenever solicited by the CA.  
Until the electronic submission via EV is completely functional, the transmission of ICSRs 
is performed by filling-in the CIOMS form I or after a process of several transmission tests 
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and procedures with INFARMED, I.P. is validated, the transmission of only serious ADR 
can be reported through the EV platform.  
 
CIOMS form I 
This document was prepared by Council for International Organizations of Medical 
Sciences (CIOMS), which is an organisation established in 1949 by a partnership between 
WHO and United Nations Educational, Scientific and Cultural Organization. This group 
develop guidelines in the pharmacovigilance area, including the CIOMS form I, which is a 
reporting form for ADR internationally recognised. 
Consequently, I also had to fill-in CIOMS forms I with the ICSRs information in order to 
send them to INFARMED, I.P. The CIOMS form I is filled-in with all the available 
information concerning the case including information related to the patient, primary 
source, suspect ADR and the suspect medicinal product. It is desirable that all the fields of 
the form are completed, but frequently not all the information is available, consequently it 
should only be ensured (in validation stage) that the minimum criteria for report are 
present. Finally, every time a suspect ADR had to be reported to INFARMED I.P., the 
CIOMS form I was sent to the Directorate of Medicines Risk Management by email. 
 
EudraVigilance database: Electronic transmission of ICSRs 
Currently, the reporting of serious ADR to INFARMED, I.P. is performed by the EV 
database since this communication channel was approved by the National CA. 
Consequently, I had the opportunity to learn the functionalities of the EV database, how it 
works, and how a case can be reported to INFARMED, I.P. 
The images outputs and cases used in this section to describe the functionalities and rules 
of the EV database are fictitious, and are intended for demonstration purposes only.  
EV database is the “European data-processing network and database management system 
which allows the reporting and evaluation of Adverse Events and ADR during clinical 
investigation and post-authorisation phase of medicinal products in the European 
Economic Area”. The creation of the EV database aims to improve the capability of 
transmission of safety information between pharmaceutical companies and the European 
CA [35].   
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The access to EV platform is by the EV web application, called EVWEB, which is a tool 
designed for electronic transmission of ICSRs to the EV database through the internet [35].  
During my internship, I accompanied and, in some cases participated in reporting of ADR 
through the EV database, by collecting and gathering all the information to be submitted in 
the platform. 
First, for reporting an ADR, it is needed to access to the EV web site [36] and then choose 
the option “Production” on the right side menu on the top of the page, as presented in 
Figure 5. 
 
 
Figure 5 – EV database web site output, available on the Eudravigilance web site [36] 
 
After left click on “Production,” a new window opens and it is needed to enter the login 
user and the password to have access to the restricted area. Then, a new window appears 
and the option EVWEB should be selected, as presented in Figure 6. Subsequently, the 
EVWEB application will open in a new browser window. 
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Figure 6 – EV Services menu, available on the Eudravigilance web site [36] 
 
The new browser window has a main menu located at the top of the screen and contains 
the default buttons and the dynamic buttons (Figure 7). 
 
Figure 7 – Output after choose the option “send ICSRs”, available on the Eudravigilance web site [36] 
 
The buttons enable to perform different activities: 
 Create and send ICSRs (button “Send ICSRs”); 
 Create and send acknowledgments (button ”Send Acks”); 
 Access to the inbox and outbox folders as also to import messages saved on the 
computer (button “WEB Trader”); 
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 Browse and perform searches on the ICSRs that were submitted by the MAH 
(button “ICSRs”); 
 Create and send XEVMPD Product Report Message (button “Send Products”);  
 Verify the XEVMPD (button “Products”);  
 Browse and perform searches on MedDra (button “MedDra”). 
Whenever there is an ICSR to report, the option “Send ICSRs” is chosen and a tree view 
appears on the left side of the application, below to the main navigation menu, as 
highlighted in Figure 7. Generally, the elements in the tree view can be expanded allowing 
the introduction of more information. 
The fields that appear on the right side are completed, but not all the fields are mandatory 
since in a large number of cases, not all information is available. Each field have 
specificities that are explained in ICH E2B (R2) guideline. 
The information provided, in the EV database, is related to, but not only: 
 Safety report: information concerning the safety report identification, date of 
transmission, type of report, date when the report was received by primary source, 
seriousness of the ADR and other information 
 Primary source, i.e., the person who reports the facts: title, name, organisation, 
country; in case of literature search the literature reference should be included and 
in case of a study, the details on trial type should also be provided 
 Patient characteristics: patient initials, birth date, age, investigational number (in 
case of a clinical trial), patient age group, patient sex; 
 Patient medical history; 
 Patient past drug therapy;  
 Reaction(s)/Event(s): reaction reported by primary source, MedDra code for 
the reaction, start date, end date, duration, outcome; 
 Test/procedure results relevant for the investigation; 
 Drug(s) information: including suspect drugs and concomitant medications 
and also drugs thought to have an interaction: Proprietary Medicinal 
Product Name, authorisation status, authorisation country, MAH, dose, 
route of administration, indication, date of start of drug, last administration 
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date, action taken (drug withdrawn, drug reduced, drug increased, dose not 
changed, unknown, not applicable; 
 Patient death (if applicable): death date and autopsy including patient cause 
of death; 
 Parent-child report (if applicable): parent information.  
Once all the fields, for which there is information available, are completed, it is selected 
the message receiver, which for the medicinal products authorised in Portugal, is the 
INFARMED, I.P. After selecting INFARMED, I.P. it is necessary to validate the case in 
the button “Validate” on the top of the screen and then, if no errors are detected a XML 
(Extensible Mark-up Language) and a RTF (Rich Text Format) file copy are saved and 
subsequently the safety case is submitted. 
The electronic transmission is based on XML files, format in which the safety message is 
sent and contains one or several ICSRs. The advantage of saving a copy in that format is 
that it is the only format accepted by the database and the only way to import a file from 
the computer to the EV database, in case of follow-up. 
After sending the message, there is a confirmation of the reception of the information 
called acknowledgment (ACK). The receiver processes the safety message and then, sends 
an ACK message informing whether the report was accepted or not and in the negative 
cases the reason(s) why.  
There are three transmission ACK codes:  
 ACK 01 – When the ICSR does not contain any errors and consequently the safety 
reports are loaded; 
 ACK 02 – When the ICSR contain errors and consequently not all safety reports are 
loaded; 
 ACK 03 – When no data can be extracted from the safety message resulting in a 
message or system error. 
Accompanying the activities related to this platform, it allowed me to observe how the EV 
database works and understand their functionalities. It was a very important task, because 
this is a new tool used in Europe for pharmacovigilance purposes and all the companies 
need to have trained collaborators in that field, in order to comply with the regulatory 
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requirements. The EV database is a complex data processing and management system that 
requires training for its use. I had the chance to learn it with the company’s EU-QPPV, 
who has the certificates that give her the competencies to work with the platform.  
 
2.2.1.4. Periodic Safety Update Reports 
Overall requirements 
Periodic Safety Update Report (PSUR) summarises and gathers data and information 
regarding the safety of a medicinal product during its lifecycle. This report is then, 
evaluated by the authorities that analyse the ratio of benefit/risk of the medicinal product in 
question. All potential risks are evaluated in order to protect public health [37]. 
PSURs are submitted with a determined frequency and consequently the information 
contained covers a determined period. The cut-off date of the data included in the PSUR is 
designated as data lock point (DLP) [37].  
The submission of the frequency of submission and DLP are laid down as a condition on 
the MA or it is determined in the list of Union reference dates and frequency of submission 
of periodic safety update reports (EURD) [34]. 
With the new pharmacovigilance legislation, the EMA created the EURD list, which is 
made public by EMA and updated monthly. This list includes active substances and 
combinations of active substances contained in medicinal products authorised in the EU. It 
was compiled in order to facilitate the harmonisation of the frequency submission of 
PSURs and DLPs for the medicinal products authorised in EU [37]. The first EURD list 
was published on October the 1
st
 2012 and came into force on April the 1
st
 2013 [34]. 
Before the new legislation, it was an option to the MAH to subscribe the PSUR Work 
Sharing and Synchronisation Project. This project included the publication of two lists: the 
PSUR Work Sharing list and the PSUR Synchronisation list. However, the accession to 
this project was voluntary as its lists did not included all active substances and combination 
of active substances present in the medicinal products authorised in EU [37]. 
The new pharmacovigilance legislation introduced another change concerning PSURs. 
These reports are not always required for generic medicines, medicines whose use is "well-
established", homoeopathic medicines and traditional herbal medicines. Depending on the 
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active substance, the EURD list demands or not the submission of PSURs in the case of 
this type of medicines [37].  
 
Working experience 
During my internship, I collaborated in PSURs preparation and submission to 
INFARMED, I.P. In order to accomplish this activity I had to collect relevant information 
and write different sections of the PSUR. I had the opportunity to follow the submission of 
PSURs to the authorities. 
First, I had to collect the information used to prepare a PSUR, which is provided by 
efficacy, effectiveness and safety sources, such as [37]: 
 Internal information related to the volume of sales of a medicinal product during the 
timeframe of the report, reference safety information (SmPC), and 
pharmaceutical/medical sales representative suspect of ADR notifications, literature 
research; 
 External information is related to spontaneous reports from health care professionals 
and consumers, regulatory authorities and safety data exchange agreements with 
external partners.  
I also had to research and collect information concerning the characteristics of the 
medicinal product (as chemical class, mechanism of action, pharmacotherapeutic group, 
ATC code and others) and regulatory authorities’ information (MAH, MA date, MA 
number(s), international bird date, EURD, and others.  
Then, I began writing the different sections of the PSUR.  
According to the Commission   Implementing Regulation (EU) No 520/2012 of 19 June 
2012, the PSUR template presents the following sections:  
 Part I: Title page including signature4 
 Part II: Executive Summary 
 Part III: Table of Contents 
1. Introduction 
2. Worldwide MA status 
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3. Actions taken in the reporting interval for safety reasons 
4. Changes to reference safety information 
5. Estimated exposure and use patterns 
6. Data in summary tabulations 
7. Summaries of significant findings from clinical trials during the reporting 
interval 
8. Findings from non-interventional studies 
9. Information from other clinical trials and sources 
10. Non-clinical Data 
11. Literature 
12. Other periodic reports 
13. Lack of efficacy in controlled clinical trials 
14. Late-breaking information 
15. Overview of signals: new, on-going, or closed 
16. Signal and risk evaluation 
17. Benefit evaluation 
18. Integrated benefit-risk analysis for authorised indications 
19. Conclusions and actions 
20. Appendices to the PSUR 
National CA and EMA have different requirements for PSUR submission [38]. For 
national procedures, INFARMED, I.P. requires that the PSUR is sent in a registered 
correspondence [38]. 
Consequently, the next step consisted on preparing the registered correspondence, 
addressed to INFARMED, I.P., which contained a signed cover letter (required by the 
National CA) and one PDF copy of the PSUR in electronic format (CD-ROM). 
Furthermore, any CD-ROM sent to INFARMED, I.P. must contain the appropriate 
identification of the product in question as the product’s name, dosage, pharmaceutical 
form, MAH and DLP. 
I also prepared the identification of the CDs, using an optical disc recording technology, 
which allows direct disc labelling. As a result, all the information considered necessary for 
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the identification of CD-ROM was directly printed on each CD-ROM by the use of 
specific software.  
During my internship, I acquired the capability to perform this task in an independent way, 
performing the management of the schedule of PSURs submission according to the DLP of 
each product and subsequently the preparation for the submission of the report. 
The preparation of PSURs was very useful since I understood how to acquire the baseline 
information for its preparation, how the benefit-risk analysis of a product is conducted and 
also, how to manage my time in order to comply with the deadlines. All the processes are 
extremely meticulous and rigorous because medicinal products are manufactured for 
persons and their safety must always be ensured. Therefore, I learned to be more rigorous 
in all the process, even in the simple ones and to pay attention to all the details to try to 
minimise the errors, since they may always arise. 
 
2.2.1.5. Risk Management Plan 
The new legislation on pharmacovigilance introduced the requirement to submit RMPs for 
all the new MA applications [23, 24]. 
The MAH has to have in place a risk management system, i.e., “a set of pharmacovigilance 
activities and interventions design identify, characterise, prevent or minimise risks relating 
to medicinal products”. All those activities should be assessed in terms of its effectiveness 
[39]. 
The preparation of a RMP of a generic medicinal product is based on the already available 
data of the innovator’s product. 
The RMP template is set out in the Commission implementing regulation (EU) No 
520/2012 of 19 June 2012. The GVPs have also a module dedicated to this matter, where 
the risk minimisation principles are discussed and the format and content of a RMP are 
presented in order to harmonise and facilitate their preparation by the MAH and 
assessment by CA [32]. 
During my training period, I participated in the preparation of RMPs, which allowed me to 
be in touch with their structure and to understand how the information is collected. The 
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structure of a RMP consists in seven parts and some parts are subdivided in modules, the 
structure of a RMP is presented below [32]: 
 Part I: Product(s) overview 
 Part II: Safety specification 
 Module SI: Epidemiology of the indication(s) and target population(s) 
 Module SII: Non-clinical part of the safety specification 
 Module SIII: Clinical trial exposure 
 Module SIV: Populations not studied in clinical trials 
 Module SV: Post-authorisation experience  
 Module SVI: Additional EU requirements for the safety specification 
 Module SVII: Identified and potential risks  
 Module SVIII: Summary of the safety concerns 
 Part III: Pharmacovigilance plan (including post-authorisation safety studies) 
 Part IV: Plans for post-authorisation efficacy studies 
 Part V: Risk minimisation measures (including evaluation of the effectiveness of 
risk minimisation activities) 
 Part VI: Summary of the risk management plan 
 Part VII: Annexes 
During my internship, I learned to prepare a RMP. I also understood, the difference 
between the requirements of a RMP for an innovator and the ones for a generic medicinal 
product. 
 
2.2.1.6. EudraVigilance Medicinal Product Dictionary 
Overall requirements 
In accordance with the Regulation No 1235/2010 of the Council of 15 December 2010, the 
EMA is responsible for setup and maintain a list of all medicinal products for human use 
authorised in the EU. As a result, the MAH had to submit electronically to EMA, until 2 
July 2012, information concerning all medicinal products of human use authorised in the 
EU through the XEVMPD. 
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Working experience 
One of my tasks was to support the EU-QPPV to submit Bluepharma’s medicinal products 
through the EV database. 
My role was to search and gather all the information needed to complete the fields 
requested. I collected and organised information, in order to allow a faster electronic 
submission.  
 This information came from: 
 Reference information, i.e. SmPC; 
 Regulatory medicinal product information (such as MAH, MA numbers, MA 
date); 
 Pharmacovigilance information. 
Electronic submission of medicinal product information 
To submit the medicinal products information we have to have access to the EV database 
according to the steps followed in the ICSR reporting; however, instead of choosing the 
option “Send ICSRs”, in this case, it is chosen the button “Send Products”, in order to open 
a window as presented in Figure 9. 
The information is inserted in the fields that appear on the right side, but not all the fields 
are mandatory (Figure 8). 
 
Figure 8 – Tree view after choose the button “Send Products”, available on the Eudravigilance web site 
[36] 
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Once all the necessary information is entered, the button “Validate” on the top of the 
screen was chosen, in order to verify if all the mandatory information was introduced and 
the data that was entered. If no errors occur, the message is ready to be sent. A XML and a 
RTF file are saved on the computer and subsequently, the XEVPRM is sent by choosing 
the button “Send”. 
In the outbox, it is possible to check if the XEVPRM was sent and in which date. In the 
case of XEVPRM, an ACK is also received. The ACK process is the same as mentioned in 
the ICSR messages section.  
Consequently, after receiving an ACK 01 (medicinal product successfully introduced on 
the database) it is recorded on the computer for compliance purposes.  
In order to manage efficiently the information sent and received, a management file was 
created, which allowed registering and understanding the type of information sent and the 
day, the ACK received and in which date and if the information was successfully entered 
in the EV database. 
Participating in these tasks allowed me to understand and observe how this new European 
tool works and presents itself, which is of extreme importance for a person that is working 
in the pharmacovigilance area. I was able to acquire knowledge concerning the company 
products that is always important when we belong to Regulatory Affairs and 
Pharmacovigilance department. 
 
2.2.2. Scientific Service 
 
2.2.2.1. Advertising of medicinal products 
Overall requirements 
The medicinal products advertising is regulated by the Decree-Law No 176/2006 of 30 
August, amended by the Decree-Law No 20/2013 of 14 February, Deliberation 
044/CD/2008 – Advertising Regulation and Ministerial Directive No. 157/2009 - National 
Council for Medicinal Products’ Advertising. 
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In accordance with the Portuguese Decree-Law No 176/2006 of 30 August  as amended, 
the medicinal products’ advertising is considered to be any kind of information, 
prospecting or incentive with the object or the effect of promoting its prescription, 
distribution, sale, purchase or consumption under any of the circumstances set out in this 
decree-law [17]. 
Institutional advertising 
Institutional advertising do not include specific reference to any medicinal product and 
only contains reference to the company. This type of advertisement is not considered 
medicinal product advertising, therefore, it is not subject to the same regulatory 
requirements [17].  
Advertising among health care professionals 
When a medicinal product advertising material is prepared for health care professionals, 
the following elements are included in the advertising peace, in a legible way [17, 40]:  
 Name of the medicinal product;  
 Essential information compatible with the SmPC, including qualitative and 
quantitative composition, pharmaceutical form, indications, posology, route of 
administration, contraindications, and undesirable effects. Other elements that may 
be included, if clinically relevant: special warnings and precautions for use and 
interaction with other medicinal products and other forms of interaction.  
 Medicinal product’s classification for dispensing purposes  
 State’s subsidies system. 
In addition, the advertising to prescription-only medicines is restrict to health care 
professionals, which implicates that the advertising is performed by means that allow the 
exclusive access to health care professionals, namely congresses, symposiums or any other 
actions or events of scientific nature. The advertising can only be performed for medicines 
with a valid authorisation or registration in the national market [9]. 
General public advertising 
Advertising to general public is only permitted for medicinal products not subject to 
medical prescription, once they do not contain substances defined as narcotic or 
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psychotropic or are subsidised by National Health Service. Advertising pieces for general 
public have at least the following elements: name of medicinal product, indispensable 
information for the rational use of the medicinal product, including therapeutic indications 
and special precautions; advice to the user to careful read the information included in the 
secondary packaging and PIL and, in case of doubt or symptoms persistence to contact the 
doctor or the pharmacist [17, 40]. 
 
Working experience 
During my internship, I participated in the activities associated with institutional 
advertising and medicinal products advertising.  
Medicinal product advertising  
I had the opportunity to accompany the preparation of an advertisement piece and then 
participate in the process. My work consisted on preparing the essential information, based 
on the medicinal product’s SmPC, to include in an advertising piece to health care 
professionals. 
INFARMED, I.P. requires the submission of a descriptive memory of any medicinal 
product advertising piece throughout the medicinal products advertising management 
system (GPUB) available on the INFARMED, I.P. website within 10 days starting on the 
date of publication of the advertising piece or the date of publication of an advertising 
piece integrated on promotion campaigns or annual plans (Figure 9) [41]. 
I accompanied the notification process to INFARMED, I.P. through the GPUB system of 
some advertising pieces. For that, we accessed INFARMED, I.P. web site, and then chose 
the option GPUB [41]. The next steps followed were: 
 Choose the option “Nova Notificação” on the left side of the screen as presented in 
Figure 9; 
 Complete the fields concerning the advertising piece data presented in Figure 10; 
 Choose the button “Criar notificação”; 
 On the left side of the screen there is a button that allows seeing/confirming the 
notification already sent. 
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Figure 9 – Notification form in GPUB, available on the INFARMED, I.P. [41] 
The scientific service is responsible for the information regarding the company’s medicinal 
products. The institutional and medicinal product advertising documentation is archived 
and maintained by a minimum period 5 years [17], consequently, I also had to archive hard 
and electronic copies of the notifications and support documentation, such as the material 
of medicinal product advertising.  
 
2.2.2.2. Information request management 
In accordance with the Decree-Law No 176/2006 of 30 August as amended, the companies 
have the obligation to have a Scientific Service responsible for providing information 
concerning the medicinal products for which the company holds a MA [17]. 
It was explained to me and I observed how the scientific service receives and manages the 
information requests. The main steps are described below: 
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1. Scientific service receives and registers all the information requests concerning 
Bluepharma medicinal products coming from consumers or health professionals and 
performs its adequately treatment and response according to whom presents the 
request.  
2. When the request is received, it is registered taking into account the requester’s 
identification, contacts, and description of the request and also the solicited response 
deadline.  
3. The information is assessed in order to verify if there is a quality or safety issue. If not, 
the request is valid and a response is prepared and sent to the requester.  
Accompanying and developing some of these tasks allowed me to gain experience in the 
advertising and information requests areas.  
 
2.2.3. Exportation 
 
2.2.3.1. Certificate of pharmaceutical product request 
Overall requirements 
When a company intends to export or register a medicinal product outside of the European 
Community, the importer country generally requires evidence of the MA and/or 
manufacturing status in the exporter country [42]. 
INFARMED, I.P. issues a Certificate of a pharmaceutical product (CPP) which complies 
with a WHO specific format. This certificate indicates whether the product meets statutory 
requirements providing details about the medicinal product, which may be licensed or 
unlicensed in Portugal. It can also be granted a certificate of a product without a MA. It is 
granted based on the Manufacturers Authorisation for exportation.  
In the certificate there are provided details about the product and its production including 
medicinal product name, dosage form, active ingredients and excipients present in the 
medicinal product, commercialisation status (if applicable), MA information (if 
applicable), manufacturer and other information.  
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In order to INFARMED, I.P. issue a certificate, the applicant must send a CPP request 
form and pay the respective fee, that is different depending on the number of products 
and/or number of doses of the medicinal product and the number of original copies 
required [43].  
 
Working experience 
During my training, I participated in the process of requesting CPPs. For that, I had to fill 
in the CPP forms for several medicinal products and the respective payment guide, in 
coordination with the financial officer, in order to pay the charged fee. 
There are specific rules for which is necessary to pay attention. INFARMED, I.P. made 
available specific rules for naming the documents that will be sent to them. The application 
form should be identified as FORM_COMS_medicine name_date, the payment guide 
should be named as GP_name of the company_date, in addition the proof of bank transfers 
is also sent and identified as TB_ company name_date [43].  
After gathering all needed documents and payment, an email is sent with all the documents 
to certificado.medicamento@infarmed.pt [43].  
 
2.2.3.2. Registration of medicines in Mozambique 
Overall requirements 
The registration of products in Mozambique is performed according to Mozambique 
National Legislation: Law No 4/98 of 14 January, Minesterial Diploma No 52/2010, and 
Law No 22/99 of May 4. 
According to the Law No 22/99 of 4 May, to register a medicinal product in this country 
the following documents are needed [44]:  
 Medical product Technical-Dossier 
 CPP of the medicinal product 
 Samples of the finished product and the packaging used in the Portuguese 
marketplace, as also the proposed mock-ups for Mozambique. 
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The registration is generally valid for 5 years from the date of its concession and then must 
be renewed. In order to maintain the medical product registered, it should be solicited its 
renewal at least 180 days prior to expiry the registration already granted [44].  
The registration process comprises two modalities: complete and simplified registration 
[44]. The simplified modality is based on the recognition of a previous authorisation 
granted in a reference country; the complete modality is based on the submission of 
complete technical dossier and is required when the simplified registration is not possible 
[44].  
 
Working experience 
During my internship, I was involved in the registration process of various products 
throughout the simplified registration, since Bluepharma’s medicinal products proposed for 
Mozambique market had already a MA in Portugal.  
The first steps followed for Mozambique authorisation included: 
 Request of CPPs, as previously described, in products already authorised in Portugal; 
 Information/documentation regarding several CTD modules (approved by National 
authorities as all the products have a MA) of the product to be registered, SmPC, 
patient leaflet (PIL), labelling, mock-ups, carton, samples, certificate of analysis of the 
raw materials and finished products, GMP certificate, manufacturing licence, and MA 
certificate. 
Subsequently, after obtaining and gathering all the previous information and 
documentation, I participated in the preparation of a technical dossier for each product, in 
Portuguese language and in accordance with the Mozambique legislation requirements. 
The technical dossier contains four parts [44]: 
 Part I – Administrative information and characteristics of the medicine 
 Part II – Chemical and Pharmaceutical Documentation  
 Part III – Documentation on safety 
 Part IV – Documentation on efficacy 
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Part I - Administrative information and characteristics of the medicine [44] 
 Part I-A: Administrative Information 
This section includes information concerning the type of process 
(complete/simplified), the proposed name for the medicine, qualitative and 
qualitative composition API and excipient (s), pharmacotherapeutic group, 
pharmaceutical form and dosage, presentation(s), shelf-life and storing condition, 
general classification for supply, applicant's name, address and manufacturing of 
finished product [44].  
The information to complete this section is based on the information contained in 
section 3.2.P. of the CTD, in the SmPC, MA and if applicable respective variations 
to the MA.  
 Part 1-B: Characteristics of the medicinal product 
1. Information contained in SmPC approved by INFARMED, I.P. 
2. PIL 
3. Labelling 
4. Mock-up 
This information is available through the consultation of the SmPC of the medicinal 
product authorised in Portugal as well its PIL, labelling and respective mock-up.  
Part II-Chemical and Pharmaceutical Documentation [44] 
 B-l-Composition 
o Quantity and quality composition of the API and excipients 
This section is prepared according to the CTD module section 3.2.P.1 – 
Description and Composition of the Drug Product. 
o Description of primary and secondary packaging 
This information is available on the CTD module section3.2.P.7 – Container 
Closure System.  
 B-2 – Manufacturing  
o Manufacturing formula 
o Description of manufacturing process and methods of control 
University of Aveiro 2013 Masters in Pharmaceutical Biomedicine 
 
    55 
The information to complete this section is available on the CTD module 
subsection 3.2.P.3.1 – Manufacture. The Batch formula is contained on the 
section 3.2.P.2 and the manufacturing process is detailed on the CDT module 
subsection 3.2.P.3.3 – Description of Manufacturing Process and Process 
Controls.  
 B-3-Raw Materials [44] 
o Chemical description of active and excipient substance 
This section is prepared according to the CTD module section 3.2.S.1. – 
General Information concerning the drug substance. 
 B-4 –Finished Product  
The most recent analytical certificates of the semi-finished and finished products 
are needed and requested to the quality control [44].  
 B-5 - Stability of Finished Product [44] 
o Duration and conditions of studies 
o Number and dimension of the batches studied 
o Proposed shelf-life and storage conditions 
This data is prepared according to the information presented on the CTD 
module 3.2.P.8. This section of the CTD is divided in subsections that provide 
different information. Subsection 3.2.P.8.1 summarises the studies undertaken 
including conditions, batches, analytical procedures and provides a discussion 
of the results and conclusions of the stability studies, being also included 
conclusions with respect to storage conditions and shelf-life. Subsection 
3.2.P.8.2 presents the post-approval stability protocol and subsection 3.2.P.8.3 
includes tabulated summary of the stability results 
 
Part III – Documentation on safety  
In this part of the dossier, it is presented a summary regarding the product safety, including 
bibliographic references of publications in international credible journals [44].  
To complete this part, the CTD module 2 (2.4 - Nonclinical Overview) is consulted in 
order to summarise the most relevant information concerning the product safety [44]. 
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Part IV – Documentation on efficacy  
This part of the dossier contains a summary of the efficacy of the medicinal product, 
including also bibliographic references published on credible journals [44]. 
The preparation of this section is based on the information included in the section 2.5 - 
Clinical overview of the product CTD.  
To submit the requested application, all the information is printed and recorded in 
electronic format. At the end, all the documentation is sent to Mozambique with the 
medicinal products samples’. 
   
2.2.3.3. Registration of medicines in Cape Verde 
Overall requirements 
Cape Verde exportation requirements are set out in the Decree-Law No 59/2006 [45]. 
According the Cape Verde Decree- Law 59/2006 of 15 December, the medicinal products 
may be imported under the provisions of the article 4 and 44 and are exempted of a MA.   
Consequently, it has to be sent to the CA an application form which contain administrative 
information concerning the medicinal product [45], including the following elements: 
 Applicant name and address  
 Medicinal name proposed 
 Dosage form and composition concerning active substance and excipients, 
including strength, presentation, route of administration, dosage and self-life.  
 Therapeutic indications  
 Information concerning the Manufacturer of API, excipients and finished product 
In addition to the above application form, it has to be sent the following documentation: 
 Copy of the MA certificate 
 CPP 
 SmPC, PIL and labelling approved on the country in which the medicinal product 
has an authorisation 
 Identification of the Manufacturer, copy of GMP certificate and manufacturer’s 
authorisation 
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Working experience 
My function was to complete the requested application form, to compile the support 
documentation and to prepare a dossier compiling all this information for each product.  
Those exportation-related activities were very enriching since I did not have previous 
knowledge in this area. Consequently, it was very challenging and stimulating to learn the 
legislation applicable to Cape Verde and Mozambique and understand the different 
requirements for each one of them. 
It was possible to conclude that Cape Verde has a similar legislation to the Portuguese one. 
In the case of Mozambique, there are specific requirements concerning the technical 
dossier preparation and also administrative requirements that are not specified in the 
legislation and consequently are difficult to predict. 
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3. Discussion 
3.1. Tasks assigned and learning outcomes 
During my internship in the Regulatory Affairs and Pharmacovigilance department at 
Bluepharma - Indústria Farmacêutica, S.A., I was able to be in touch with and participate 
in all the Pharmacovigilance tasks/activities, as well as, in very interesting Regulatory 
Affairs tasks, namely those related to the registration and exportation of medicinal 
products in Mozambique and Cape Verde. 
My curricular internship was most of the time focused on pharmacovigilance activities. I 
only had contact with the Regulatory Affairs activities within the scope of the above 
mentioned exportation processes. It was a great opportunity to understand my interest on 
the pharmacovigilance area. 
This internship allowed me to be in contact with the real work environment and to perform 
different tasks that helped me to acquire and upgrade my soft and hard skills and to 
improve my work capability; however is a continuous learning process that will not end for 
sure with this curricular internship.  
Hard skills 
I was able to: 
 Collaborate in the development and implementation of the company’s 
pharmacovigilance system; 
 Understand and to consult national and international regulation and guidelines, 
including GVP; 
 Manage, prepare and participate in the submission process of PSURs to CA; 
 Accompany and participate in the collection, collation, follow-up and reporting of 
ICSRs; 
 Perform literature search using search techniques in worldwide databases; 
 Participate in the preparation of RMP; 
 Understand and participate in scientific service activities; 
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 Prepare and participate in the submission process of specific documentation 
(product dossier and support documentation and material) for the registration of 
medicinal products in Mozambique and Cape Verde. 
Soft skills 
One important skill developed was the responsibility sense since the activities performed in 
the department are of extreme importance and have a high impact on the company. All the 
activities must be performed with rigour, accuracy and attention must be paid to all the 
details. Hence, I learned to be more meticulous in all the processes, even in the simple ones 
and to pay attention to all details to try to minimise errors that may arise. 
Different tasks and deadlines characterised this experience and consequently time 
management and organisational skills were developed. I learned to plan my days in 
advance and to organise my tasks/activities according with their priority/importance, in 
order to accomplish all of them in a quick and efficient way. 
The development of verbal and written skills was also essential to discuss ideas on an 
assertive way as well as to prepare documentation. 
Other important skill improved was self-assessment since it is essential to understand why 
mistakes occur, what can be improved, and the better means to overcome the gaps 
encountered. It is also important to have a continuous willingness to increase knowledge 
and skills.  
During my internship, I faced new situations that contributed for improving my autonomy, 
critical thinking and problem solving skills. I overcame these situations by searching for 
solutions and discussing my ideas with my colleagues.  
These capacities were, in a certain way, acquired during my academic journey due to the 
teaching methodology used – Problem Based Learning. This methodology requires 
students to be autonomous and work in team. During my Degree in Biomedical Sciences, I 
had tutorial sessions in which every week new problems/real life cases were discussed and 
solved in group. I was always encouraged to analyse, in a critical way, the problems in 
order to generate hypothesis and acquire information to solve them. This teaching method 
allowed me to be prepared for facing new situations and always look for solutions. 
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All the objectives initially proposed were achieved. This learning process was possible due 
to my Degree in Biomedical Sciences and Master’s Degree in Pharmaceutical 
Biomedicine, which provided me a good background to conduct the assigned tasks. But 
also, because of the support and guidance provided by my department colleagues that were 
always available and in particular, the company’s EU-QPPV, who guide me during all the 
process and contributed for acquiring new skills in pharmacovigilance and regulatory 
affairs area.  
Over the time I gained autonomy for developing tasks in an independently way, but always 
being guided and supported by the department colleagues.  
 
3.2. Difficulties 
Pharmaceutical Industry is facing new challenges due to the new legislation on 
pharmacovigilance, which has introduced new requirements and MAH responsibilities that 
affect all the medicinal product lifecycle. As a consequence, the pharmaceutical companies 
had to begin an adaptation and adjustment period to comply with the new obligations. 
Due to the new legislation, there was the necessity to develop and implement new 
processes and procedures and/or to review the existing ones and to train the collaborators 
for the new European pharmacovigilance system. The adaption process to a new legislation 
is not an easy process involving resources and time.  
The European pharmacovigilance system suffered several deep modifications, making it 
even more challenging. In order to guide the different stakeholders in the implementation 
of the new system, it was published the Commission Implementing Regulation as well 
GVP. However, not all the GVP are already finished, and some of them are not yet 
published since they are in revision. On the other hand, EMA is not capable to fully ensure 
the functionality and all the expected capabilities of the European Pharmacovigilance 
System yet. Therefore, the pharmaceutical industry is following the new legislation 
requirements, but in some areas, it is needed to take into account the transitory 
arrangements that had suffered some modifications during my internship period. 
It was not a simple process, but was very challenging, since the existing processes and 
SOPs in place needed to be reviewed in order to comply with the new requirements, I had 
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the chance to participate in their development. I also had the opportunity of seeing and 
collaborating in the creation and implementation of a pharmacovigilance system in a 
pharmaceutical company that gave me the chance to learn and develop new skills in the 
pharmacovigilance area.  
The transition from the academic environment to the professional environment was also 
difficult to me since I had to adapt to a new group of people and a new place, and over the 
time new responsibilities arose. However, the process was easier due to the support 
received by all the department colleagues and the good work environment encountered.  
My communication skills were also a problem to me, since I am a shy person and in that 
area, verbal communication skills are essential to share ideas and transmit our opinion. 
Although I understand that I have a long way to make, I think that I was capable to develop 
some communication skills and over the time became more confident in expressing my 
opinion.  
Time management is not always simple. With time, new tasks and new responsibilities 
arose and it was crucial to learn to manage the time and the activities, in order to always 
comply with the deadlines. 
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4. Conclusion 
This report intends to present my experience in the curricular internship describing the 
activities performed, the skills acquired and lessons learned during that period.  
The experience in a company environment was very enriching, because it allowed me to 
apply the theoretical knowledge acquired during my degree in Biomedical Science as well 
as in my Master’s Degree in Pharmaceutical Biomedicine. It was a useful complement to 
my academic training.  
The partnerships established between the university and companies are extremely valuable 
since it enables that the recent graduates have contact with the working environment and 
establish a contact network, being that a competitive advantage to the ones that never had 
that experience. 
This experience gave me the possibility to reflect on my weaknesses and strengths, as well 
as, my capability to handle with stressful and challenging real life situations, always trying 
to improve the less positive aspects. In addition, it contributed to analyse my work 
capabilities and the way I listened to the advices and placed them into practice  
I believe that during my curricular internship, all the objectives laid out were accomplished 
and the difficulties encountered were overcame. My academic background was a useful 
tool to face this challenge in the best way.  
In addition to the tangible outcomes summarised in soft and hard skill, this report is not 
enough to describe the values and advices that were transmitted to me during this period, 
which were precious to my personal and academic development and contributed for me to 
become a better professional in the near future.  
In conclusion, this curricular internship was a great and useful experience, relevant to my 
academic and professional development and that allowed me to grow as person and as a 
professional. However, in this field it is essential to have in mind that it is required 
continuous willingness to learn and never be satisfied with ourselves.  
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